Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Mark Stevenson

BSc (Hons); PhD


Postdoctoral Researcher

My current research focuses on understanding the mechanisms resulting in endocrine tumour formation and developing targeted therapies particularly for pancreatic, pituitary and parathyroid tumours (Thakker, Oxford). By identifying and understanding the underlying genetic defects, we aim to establish improved diagnostic tools and targeted therapies that can be translated into improved patient care. This has included characterizing models of hyperparathyroidism-jaw tumour syndrome and multiple endocrine neoplasia type 1 (MEN1), and use of a somatostatin analogue to treat pancreatic and pituitary tumours in in vivo models.

Prior to this I have studied the role of protein arginine methyltransferase 5 (PRMT5) in the growth of ovarian tumour cells (La Thangue, Oxford), and have a broad interest in the field of genetic therapies, particularly in regard to vector development for systemic administrations for the treatment of cancer which included developing targeted adenoviral vectors for the treatment of prostate cancer (Seymour, Oxford). I have also worked on the detection of the human papillomavirus type 16 E2 regulatory protein in cervical tissue (Maitland, York).

My PhD was performed at the University of Birmingham and involved the development of in-situ hybridisation for the cytogenetic analysis of Allium.

Recent publications

More publications